Hyperoxaluria – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hyperoxaluria – Drugs In Development, 2024 report and make more profitable business decisions.
Hyperoxaluria, a rare condition, manifests with recurrent kidney and bladder stones, often progressing to life-threatening end-stage renal disease (ESRD). The condition arises from the overproduction of oxalate, leading to abnormally high levels in urine. Primary hyperoxaluria types 1, 2, and 3 are caused by mutations in the AGXT, GRHPR, and HOGA1 genes, respectively. These genes guide the production of enzymes crucial for breaking down amino acids and other compounds. The enzyme from the HOGA1 gene plays a role in amino acid breakdown, resulting in the formation of glyoxylate, further processed by enzymes from the AGXT and GRHPR genes.
The Hyperoxaluria drugs in development market research report provide comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hyperoxaluria | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 17 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hyperoxaluria therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hyperoxaluria pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hyperoxaluria treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amarna Therapeutics BVArbor Biotechnologies Inc
Biocodex
BioMarin Pharmaceutical Inc
Cantero Therapeutics Inc
Curigin Co Ltd
Federation Bio Inc
Intellia Therapeutics Inc
Novo Nordisk AS
OxaluRx Inc
Oxidien Pharmaceuticals LLC
OxThera AB
Scarlet Therapeutics Ltd
Synlogic Inc
Vivet Therapeutics SAS
Yaotang (Shanghai) Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hyperoxaluria reports